Description: | Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFR? (platelet-derived growth factor receptor ?). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1]. |